Cyramza 500 mg Injection

Description

Cyramza 500 MG injection are manufactured by Eli Lilly and Company and contain 500 mg of Ramucirumab per injection. Each Vial includes Single vial, making Cyramza 500 MG injection an effective option for Bone Cancer . Prescription Required from your healthcare provider to purchase Ramucirumab medicine. Indogenmed deals in all type of generic Ramucirumab medicine.

Benefits

• Targets VEGFR-2, a key driver of tumor angiogenesis

• May help slow tumor growth by reducing blood supply to cancer cells

• Used in several advanced or metastatic cancers

• Can be used alone or in combination with chemotherapy depending on treatment protocols

• Administered under medical supervision in specialized oncology settings

Indications and Usage

Cyramza (ramucirumab) may be prescribed for adults with:

• Advanced or metastatic gastric (stomach) cancer or gastroesophageal junction cancer

• Metastatic colorectal cancer (mCRC) in combination with chemotherapy

• Non-small cell lung cancer (NSCLC) in combination with other treatments

• Hepatocellular carcinoma (HCC) in selected patients

• Other approved oncology indications depending on regional regulatory approvals

Use is determined by an oncologist based on cancer type, prior therapies, and clinical guidelines.

How it Works

Ramucirumab is a monoclonal antibody that specifically targets vascular endothelial growth factor receptor-2 (VEGFR-2), a receptor involved in the development of new blood vessels. Tumors rely on angiogenesis to obtain nutrients and oxygen needed for continued growth.

By binding to VEGFR-2, ramucirumab blocks the interaction between this receptor and its natural ligands. This inhibition interferes with angiogenesis, potentially limiting the tumor’s ability to form new blood vessels. As a result, cancer cell growth and spread may be slowed when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

• Cyramza is administered as an intravenous infusion in a hospital or oncology clinic.

• Infusions are typically given every 2 or 3 weeks, depending on the treatment regimen.

• The dosage is calculated based on body weight and treatment protocol.

• Infusions are administered by trained healthcare professionals.

• Treatment schedules and duration depend on clinical response, tolerance, and physician guidance.

Side Effects

Common side effects

• Fatigue

• High blood pressure (hypertension)

• Diarrhea

• Headache

• Decreased appetite

• Low white blood cell counts (especially when combined with chemotherapy)

Serious side effects

• Severe bleeding or hemorrhage

• Gastrointestinal perforation

• Severe hypertension

• Blood clots or thromboembolic events

• Delayed wound healing

• Infusion-related reactions

Patients should contact their healthcare provider immediately if severe symptoms occur.

Warning and Precaution

• Risk of severe bleeding or hemorrhage

• Possible gastrointestinal perforation

• High blood pressure requiring monitoring

• Increased risk of blood clots

• May cause delayed wound healing; inform doctors before surgery

• Risk of infusion-related reactions

• Potential proteinuria (protein in urine) requiring monitoring

• Pregnancy should be avoided during treatment

Patient Guidance

• Treatment will be administered by healthcare professionals in a clinical setting

• Attend all scheduled infusion appointments and follow-up visits

• Monitor blood pressure and report symptoms such as severe headaches or chest pain

• Inform healthcare providers about all medicines and supplements being taken

• Report symptoms such as bleeding, abdominal pain, or unusual swelling

• Follow your oncology team’s guidance regarding diet, hydration, and activity

Clinical Trial & Approvals

Ramucirumab has been evaluated in several clinical trials across different cancers. Studies such as the REGARD and RAINBOW trials demonstrated clinical benefit in patients with advanced gastric or gastroesophageal junction cancer. Based on clinical trial data, ramucirumab has received approvals from regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific oncology indications.

References

• U.S. Food and Drug Administration (FDA) – Cyramza Prescribing Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125477s043lbl.pdf

• European Medicines Agency (EMA) – Cyramza (ramucirumab) Product Information
  https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza

• National Cancer Institute – Ramucirumab Drug Information
  https://www.cancer.gov

• Drugs.com – Cyramza (ramucirumab) Drug Information
  https://www.drugs.com/cyramza.html

• ClinicalTrials.gov – Ramucirumab Clinical Studies
  https://clinicaltrials.gov

Prescription & documentation note

Cyramza 500 mg Injection is typically supplied against a valid prescription and administered in a clinical setting. For international supply requests, patients may need to provide documentation such as a physician’s prescription, medical records, and identification, depending on destination country regulations. MedsMonk can assist with documentation guidance where applicable.